David Pacitti - 27 Jul 2026 Form 4 Insider Report for AVANOS MEDICAL, INC. (AVNS)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
28 Jul 2026, 17:39:22 UTC
Prior SEC filing
25 Jun 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ John Fischer, as attorney-in-fact for David Pacitti

Key filing fact

David Pacitti filed Form 4 for AVANOS MEDICAL, INC. (AVNS) on 28 Jul 2026.

Key facts

  • This page summarizes David Pacitti's Form 4 filing for AVANOS MEDICAL, INC. (AVNS).
  • 4 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 28 Jul 2026, 17:39.

Change

  • Previous filing in this sequence was filed on 25 Jun 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001722733 Primary reporting owner

Pacitti David

Relationship
Chief Executive Officer
Address
5405 WINDWARD PKWY, ALPHARETTA
Signature
/s/ John Fischer, as attorney-in-fact for David Pacitti
Signature date
28 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AVNS transaction

Common Stock

Disposed to Issuer

Transaction value
Shares
-322,194
Change %
-100%
Price
$25.00*
Shares after
0
Date
27 Jul 2026
Ownership
Direct
Footnotes
F1, F2
AVNS transaction

Common Stock

Award

Transaction value
Shares
+444,730
Change %
Price
$0.000000*
Shares after
444,730
Date
27 Jul 2026
Ownership
Direct
Footnotes
F3, F4, F5
AVNS transaction

Common Stock

Disposed to Issuer

Transaction value
Shares
-444,730
Change %
-100%
Price
$25.00*
Shares after
0
Date
27 Jul 2026
Ownership
Direct
Footnotes
F3, F4, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AVNS transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares
-239,354
Change %
-100%
Price
Shares after
0
Date
27 Jul 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
239,354
Exercise price
$13.69
Footnotes
F6, F7
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

David Pacitti is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 7 footnotes

Footnote F1

Pursuant to the Agreement and Plan of Merger, dated as of April 13, 2026 (as it has been or may be amended, supplemented, waived or otherwise modified in accordance with its terms, the Merger Agreement), by and among the Issuer, A-AV Holdco I, Inc., a Delaware corporation, and A-AV MergerSub, Inc. (Parent), a Delaware corporation and a wholly-owned subsidiary of Parent, each share of the Issuer's common stock, par value $0.01 per share, that was issued and outstanding immediately prior to the effective time of the Merger (the Effective Time), which occurred on July 27, 2026, was converted into and exchanged for the right to receive $25.00 per share in cash, without interest (the Merger Consideration), payable in accordance with the terms and subject to the conditions of the Merger Agreement.

Footnote F2

Includes 270,774 restricted stock units of the Company which were subject to only time-based vesting conditions (each, a Company TRSU). Pursuant to the Merger Agreement, these Company TRSUs were canceled immediately prior to the Effective Time of the Merger and converted into the right to receive an amount in cash determined by multiplying (i) the Merger Consideration by (ii) the number of shares of Common Stock the reporting person would have been entitled to receive if such Company TRSUs had vested in full (less applicable tax withholdings)

Footnote F3

Represents the deemed acquisition and disposition of Common Stock pursuant to restricted stock units that were subject to performance-based vesting conditions (each, a Company PRSU), which were previously granted to the reporting person.

Footnote F4

Pursuant to the Merger Agreement, these Company PRSUs were canceled immediately prior to the Effective Time of the Merger and converted into the right to receive an amount in cash determined by multiplying (i) the Merger Consideration per share of Common Stock by (ii) the number of shares of Common Stock such holder would have been entitled to receive if such Company PRSU award had vested based on (A) actual performance against performance metrics for any one-year performance period completed prior to the Effective Time, (B) for any one-year performance period that is in progress as of the Effective Time, the greater of (1) actual achievement against performance metrics and (2) its target level (although, as referenced below, such awards will be converted at target level with a potential true-up), and (C) deemed achievement at target level for any one-year performance period that has not yet commenced as of the Effective Time (less applicable tax withholdings).

Footnote F5

The amount reported represents the aggregate number of Company PRSUs paid out to the Reporting Person at (or within 15 business days following) the Effective Time based on target performance for fiscal year 2026. In the event that actual performance for fiscal year 2026 exceeds target, the reporting person will receive a true-up payment. The maximum aggregate number of Company PRSUs that the reporting person could earn based on actual performance for fiscal year 2026 is 754,331.

Footnote F6

These options were originally scheduled to vest 30% on March 13, 2027, 30% on March 13, 2028 and 40% on March 13, 2029.

Footnote F7

Pursuant to the Merger Agreement, these stock options were canceled immediately prior to the Effective Time of the Merger and converted into the right to receive an amount in cash determined by multiplying (i) the excess of (A) the Merger Consideration minus (B) the exercise price payable in respect of each share of Common Stock subject to such stock option, by (ii) the number of shares of Common Stock the reporting person would have been entitled to receive upon exercise if such stock option award had vested in full (less applicable tax withholdings). Company stock options with an exercise price per share that exceeds the Merger Consideration were canceled for no consideration, which cancelations are exempt from Section 16 of the Securities Exchange Act of 1934, as amended, pursuant to Rules 16a-4(d) and 16b-6(d) thereunder.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .